BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) by 3.0% in the third quarter, Holdings Channel reports. The firm owned 53,360 shares of the biotechnology company’s stock after buying an additional 1,530 shares during the period. Ensign Peak Advisors Inc’s holdings in BioCryst Pharmaceuticals were worth $672,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in BCRX. Fairfield Bush & CO. acquired a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth $34,000. Lazard Asset Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth $57,000. Huntington National Bank boosted its position in shares of BioCryst Pharmaceuticals by 24.0% in the 3rd quarter. Huntington National Bank now owns 5,582 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 1,081 shares in the last quarter. Amundi purchased a new position in BioCryst Pharmaceuticals in the 2nd quarter worth $86,000. Finally, Canada Pension Plan Investment Board purchased a new position in BioCryst Pharmaceuticals in the 3rd quarter worth $102,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

BioCryst Pharmaceuticals Stock Up 0.2 %

Shares of BioCryst Pharmaceuticals stock opened at $8.31 on Tuesday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $7.61 and a twelve month high of $18.00. The business has a 50-day moving average price of $10.02 and a 200 day moving average price of $11.75. The firm has a market cap of $1.57 billion, a PE ratio of -6.25 and a beta of 2.03.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) last announced its quarterly earnings results on Tuesday, February 21st. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.19). The company had revenue of $79.50 million during the quarter, compared to analysts’ expectations of $74.18 million. During the same period in the previous year, the company posted ($0.40) EPS. The firm’s quarterly revenue was up 68.4% compared to the same quarter last year. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.98 EPS for the current year.

Insider Activity at BioCryst Pharmaceuticals

In related news, insider Helen M. Thackray sold 3,125 shares of BioCryst Pharmaceuticals stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $10.89, for a total value of $34,031.25. Following the completion of the transaction, the insider now owns 133,275 shares in the company, valued at approximately $1,451,364.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Anthony Doyle sold 5,700 shares of BioCryst Pharmaceuticals stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $10.90, for a total value of $62,130.00. Following the sale, the chief financial officer now directly owns 163,966 shares in the company, valued at approximately $1,787,229.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Helen M. Thackray sold 3,125 shares of BioCryst Pharmaceuticals stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $10.89, for a total value of $34,031.25. Following the completion of the sale, the insider now owns 133,275 shares in the company, valued at $1,451,364.75. The disclosure for this sale can be found here. Insiders sold a total of 123,370 shares of company stock worth $1,292,702 in the last 90 days. Corporate insiders own 5.00% of the company’s stock.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of research analyst reports. Needham & Company LLC upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Wednesday, February 22nd. JMP Securities restated a “market outperform” rating and issued a $16.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 22nd. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 22nd. Finally, Barclays reduced their target price on BioCryst Pharmaceuticals from $12.00 to $10.00 in a research note on Friday, December 16th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.11.

BioCryst Pharmaceuticals Profile

(Get Rating)

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever.